Bibiografia
RIFERIMENTI BIBLIOGRAFICI
Albers S-, Mir T.S., Haddad M., Läer S. “N-Terminal pro-brain natriuretic peptide:
normal ranges in the pediatric population including method comparison and interlaboratory variability”. Clin Chem Lab Med. (2006); 44(1): 80-5.
Anderson P.A., Sleeper L.A., Mahony L., Colan S.D., Atz A.M, Breitbart R.E., Gersony W.M., Gallagher D., Geva T., Margossian R., McCrindle B.W., Paridon S., Schwartz M., Stylianou M., Williams R.V., Clark B.J. “Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study”. J Am Coll Cardiol. (2008);
52(2): 85-98.
Ationu A., Burch M., Singer D., Littleton P., Carter N.. “Cardiac transplantation affects ventricular expression of brain natriuretic peptide”. Cardiovasc Res. (1993); 27(2): 188- 91.
Ationu A., Sorensen K., Whitehead B., Singer D., Burch M., Carter N.D.. “Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children--a three year follow up”. Cardiovasc Res. (1993); 27(12): 2135-9.
Bakker J., Gies I., Slavenburg B., Bekers O., Delhaas T., van Dieijen-Visser M..
“Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood”. Clin Chem. (2004) 50(12): 2465.
Bibiografia
Banfi G., Migliorini S., Dolci A., Noseda M., Scapellato L., Franzini C.. “B-type natriuretic peptide in athletes performing an Olympic triathlon”. J Sports Med Phys Fitness (2005); 45(4):529-31.
Bar-Oz B., Lev-Sagie A., Arad I., Salpeter L., Nir A.. “N-terminal pro-B-type natriuretic peptide concentrations in mothers just before delivery, in cord blood, and in newborns”. Clin Chem. (2005); 51(5): 926-7.
Baumgartner H., Bonhoeffer P., De Groot N.M., de Haan F., Deanfield J.E., Galie N., Gatzoulis M.A., Gohlke-Baerwolf C., Kaemmerer H., Kilner P., Meijboom F., Mulder B.J., Oechslin E., Oliver J.M., Serraf A., Szatmari A., Thaulow E., Vouhe P.R., Walma E.; “Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC)”. Eur Heart J. (2010); 31(23): 2915-57.
Beltowski J., Wojcicka G. “Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research” . Med Sci Monit . (2002); 8: RA39-RA52.
Benedict C.R.. “Neurohumoral aspects of heart failure”. Cardiol Clin. (1994); 12(1): 9- 23. Bentzen H., Pedersen R.S., Pedersen H.B., Nyvad O., Pedersen E.B.. “Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure”. Clin Sci (Lond). (2003); 104(3): 303-12.
Bibiografia
Berry J.G., Askovich B., Shaddy R. E., Hawkins J. A., Cowley C.G.. “Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease”. Pediatric Cardiolvasc Surg. (2006); 131(3): 632-8.
Bettencourt P., Friões F., Azevedo A., Dias P., Pimenta J., Rocha-Gonçalves F., Ferreira A. “Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure”. Int J Cardiol. (2004); 93(1): 45-8.
Bluestein B.I., Belenky A., Lin S., et al. “Development of an automated test for B-type natriuretic peptide (BNP) as an aid in the diagnosis and evaluation of congestive heart failure on the Bayer ADVIA Centaur chemiluminescent system”. Clin Chem (2002); 48:
A85.
Boomsma F., van den Meiracker A.H. “Plasma A.. and B-type natriuretic peptides:
physiology, methodology and clinical use”. Cardiovasc Res. (2001); 51(3): 442-9.
Cannesson M., Bionda C., Gostoli B., Raisky O.., di Filippo S., Bompard D., Védrinne C., Rousson R., Ninet J., Neidecker J., Lehot J.J.. “Time course and prognostic value of plasma B-type natriuretic peptide concentration in neonates undergoing the arterial switch operation”. Anesth Analg. (2007); 104(5): 1059-65.
Cantinotti. M, Clerico A., Murzi M.. “Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology”.
Bibiografia
Clin Chim Acta (2008); 390: 12–22.
Cantinotti M., Giovannini S., Murzi B., et al. “Review: diagnostic, prognostic and therapeutic relevance of Btype natriuretic peptide assay in children with congenital heart diseases”. Clin Chem Lab Med (2011); 49: 567-80.
Cantinotti M., Storti S., Crocetti M., Assanta N., Murzi B., Clerico A.. “Decision levels for plasma B-type natriuretic peptide assay to diagnose significant cardiovascular disease in children”. J Am Coll Cardiol. (2010a); 55(11): 1166-7.
Cantinotti M., Storti S., Parri M.S., Murzi M., Clerico A.. “Reference values for plasma B-type natriuretic peptide in the first days of life”. Clin Chem. (2009); 55(7): 1438-40.
Cantinotti M., Storti S., Ripoli A., Zyw L., Crocetti M., Assanta N., Murzi B., Clerico A.. “Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life”. Clin Chem Lab Med. (2010b); 48(9): 1333-8.
Cardarelli R., Lumicao T.G. Jr. “ B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians”. J Am Board Fam Pract. (2003) 16(4): 327-33.
Cetin I., Tokel K., Varan B., Orün U., Aşlamaci S.. “Evaluation of right ventricular function by using tissue Doppler imaging in patients after repair of tetralogy of fallot”
Bibiografia
Echocardiography. (2009); 26(8): 950-7.
Cheung E.W., Lam W.W., Chiu C.S., Chau A.K., Cheung S.C., Cheung Y.F.. “Plasma brain natriuretic peptide levels, right ventricular volume overload and exercise capacity in adolescents after surgical repair of tetralogy of Fallot”. Int J Cardiol. (2007); 121(2):
155-62.
Choi B.M., Lee K.H., Eun B.L., Yoo K. H., Hong Y. S., Son C. S., Lee J. W.. “Utility of rapid Btype natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants”. Pediatrics. (2005); 115: e255–61.
Claudius I., Lan Y.T., Chang R.K., Wetzel G.T., Alejos J. “Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients”. Am J Cardiol. (2003); 92(11): 1368-70.
Clerico A., Del Ry S., Giannessi D.. “Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods”. Clin Chem. (2000);
46(10):1529-34.
Clerico A., Del Ry S., Maffei S., Prontera C., Emdin M., Giannessi D.. “The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex”. Clin Chem Lab Med. (2002b) 40(4): 371-7.
Bibiografia
Clerico A., Emdin M.. “Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review”. Clin Chem. (2004); 50(1): 33- 50.
Clerico A., Fontana M., Ripoli A., Emdin M.. “ Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure”. Adv Clin Chem.
(2009b); 48: 163-79.
Clerico A., Fontana M., Vittorini S., Emdin M.. “The search for a pathophysiological link between gender, cardiac endocrine function, body mass regulation and cardiac mortality: Proposal for a working hypothesis”. Clin Chim Acta (2009); 405: 1-7.
Clerico A., Passino C., Emdin M.. “When gonads talk to the heart sex hormones and cardiac endocrine function”. J Am Coll Cardiol (2011); 58: 627-8.
Clerico A., Pronera C., Emdin M., Passino C., Storti S., Poletti R. Zyw L., Zucchelli G.
C.. “Analytical performance and diagnosyic accurancy of immunometric assays for the measurement ofof plasma B-type natriuretic peptide (BNP) and N-terminal pro BNP.
Clin Chem (2005a); 51: 445-7.
Clerico A., Recchia F. A., Emdin M.. “ Cardiac endocrine function in an essential component of the homeostatic regulation network: physiological and clinical implications”. Am J Physiol Heart Circ Physiol. (2006a) 290(1):H17-29.
Bibiografia
Clerico A., Zucchelli G.C., Pilo A., Emdin M.. “ Clinical relevance of biological variation of B-type natriuretic peptide”. Clin Chem. (2005b); 51(5): 925-6.
Clerico A., Zucchelli G. C., Pilo A., Passino C., Emdin M.. “Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay”. Clin Chem Lab Med. (2006b); 44(4): 366-78.
Clerico A.. “Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease?”. Clin Chem Lab Med. (2002a); 40(8):752-60.
Cowley C.G., Bradley J.D.., Shaddy RE.. “B-type natriuretic peptide levels in congenital heart disease”. Pediatr Cardiol (2004); 25: 336-40.
Czernik C., Lemmer J., Metze B., Koehne P. S., Mueller C., Obladen M.. “B-type natriuretic peptide to predict ductus intervention in infants -28 weeks”. Pediatr Res (2008); 64: 286–90.
Davlouros P. A., Karatza A. A., Xanthopoulou I., Dimitriou G., Georgiopoulou A., Mantagos S., Alexopoulos D. “Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease”. Int J Cardiol (2011): 147:42-6.
De Bold A. J., Borestein H.B., Veress A. T., Sonnemberg H.. “A rapid and important
Bibiografia
natriuretic response to intravenous injection of atrial myocardial extracts in rats”. Life Sci (1981), 328: 89-94.
De Bold A. J.. “Atrial natriuretic factor: a hormone produced by the heart” Science (1985), 230:767-70.
De Bold A.J., Bruneau B.G., Kuroski de Bold M.L.. “Mechanical and neuroendocrine regulation of the endocrine heart.” Cardiovasc. Res. (1996) 31(1): 7-18.
De Lemos J.A., McGuire D.K., Drazner M.H.. “B-type natriuretic peptide in cardiovascular disease.” Lancet. (2003) 362: 316-22.
De Long E.R., De Long D.M., Clarke-Pearson D.L.. “Comparing the areas under two or more correlated ROC curves: a nonparametric approach”. Biometrics 1988; 44: 837-45.
Dodge-Khatami A., Büchel E.V., Knirsch W., Kadner A., Rousson V., Dave H.H., Bauersfeld U., Prêtre R.. “Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular dilatation”. Ann Thorac Surg. (2006); 82(3): 983-8.
Dolci A., Dominici R., Cardinale D., Sandri M. T., Panteghini M. “ I marcatori Biochimici nella valutazione della cardiotossicità da farmaci antineoplastici: analisi sistematica della letteratura e raccomandazioni per il loro utilizzo”. G. ital Cardiol.
(2006); 7: 604-11.
Bibiografia
Doust J.A., Glasziou P.P., Pietrzak E., Dobson AJ.. “A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure”. Arch Intern Med. (2004);
164(18): 1978-84.
Eerola A., Jokinen E., Boldt T., Pihkala J.. “The influence of percutaneous closure of patent ductus arteriosus on left ventricular size and function: a prospective study using two- and three-dimensional echocardiography and measurements of serum natriuretic peptides”. J Am Coll Cardiol. (2006); 47(5): 1060-6.
El-Khuffash A., Molloy E.J.. “Are B-type natriuretic peptide (BNP) and N-terminal- BNP useful in neonates?”. Arch Dis Child (2007); 92: F320-4.
Emdin M., Clerico A., Clemenza F.. “Recommendations for the clinical use of cardiac natriuretic peptides”. Ital Heart J. (2005); 6: 430-46.
Emdin M., Vittorini S., Passino C., Clerico A.. “Old and new biomarkers of heart failure”. Eur J Heart Fail (2009); 11:331-5.
Espiner E. A.. “ Physiology of natriuretic peptides”. J Intern Med. (1994); 235(6): 527- 41.
Farombi-Oghuvbu I., Matthews T., Mayne P.D., Guerrin H., Corcoran J. D.. “Nterminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus”. Arch
Bibiografia
Dis Child (2008); 93:F257–60.
Festa P., Ait-Ali L., Prontera C., De Marchi D., Fontana M., Emdin M., Passino C..
“Amino-terminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients”.
Pediatr Cardiol. (2007); 28(5): 339-45.
Fischer Y., Filzmaier K., Stiegler H., Graf J., Fuhs S., Franke A., Janssens U., Gressner A.M.“Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide”. Clin Chem. (2001); 47(3): 591-4.
Flynn PA.., da Graca R.L., Auld P.A., et al. “The use of a bedside assay for plasma B- type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates”. J Pediatr (2005); 147: 38–42.
Galvani M., Ottani F., Oltrona L., Ardissino D., Gensini G.F., Maggioni A.P., Mannucci P.M., Mininni N., Prando M.D., Tubaro M., Vernocchi A., Vecchio C.;
Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). “N-terminal pro- brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes”. Circulation. (2004); 110(2): 128-34.
Geiger R., Hammerer-Lercher A., Url C., Schweigmann U., Puschendorf B., Sommer
Bibiografia
R., Stein J.I., Mair J.. “NT-proBNP concentrations indicate cardiac disease in pediatric patients”. Int J Cardiol. (2007); 123(1): 63-5.
Gessler P., Knirsch W., Schmitt B., Rousson V., von Eckardstein A.. “Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery”. J Pediatr. 2006; 148(3): 372-6.
Goetze J. P., Gore A., Moller C. H., Steinbrüchel D. A., Rehfeld J. F., Nielsen L. B..
“Acute myocardial hypoxia increases BNP gene expression”FASEB J. (2004) 18 (15):
1928-30.
Goetze J.P., Rehfeld J.F., Videbaek R., Friis-Hansen L., Kastrup J.. “B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts”. Eur J Heart Fail.
(2005) 7(1): 69-74.
Goetze J.P.. “Biosynthesis of cardiac natriuretic peptides”. Results Probl Cell Differ.
(2010); 50: 97-120.
Halse K. G., Lindegaard M. L., Goetze J. P., Damm P., Mathiesen E. R., Nielsen L. B..
“Increased plasma pro-B-type natriuretic peptide in infants of women with type 1 diabetes”. Clin Chem. (2005); 51(12): 2296-302.
Hammerer-Lercher A., Geiger R., Mair J., Url C., Tulzer G., Lechner E., Puschendorf
Bibiografia
B., Sommer R.. “Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients”. Clin Chem.
(2006); 52(7): 1415-9.
Hammerer-Lercher A., Puschendorf B., Fuchs D., Mair J., Tews G., Shebl O., Sommer R.. “Possible placental exchange of neopterin as indicated by significant correlations in matched maternal neonatal blood samples at delivery”. Clin Chim Acta. (2006); 365(1- 2): 350-1.
Hammerer-Lercher A., Puschendorf B., Sommer R., Mair J., Tews G., Shebl O., Hawa G., Maitzen S., Woloszczuk W.. “Natriuretic peptides correlate between newborn twins but not between twins and their mothers”. Clin Chim Acta. (2007); 377(1-2): 279- 80.
Hartmann F., Packer M., Coats A.J., Fowler M.B., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Anker S.D., Amann-Zalan I., Hoersch S., Katus H.A..
“Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial”. Circulation. (2004); 110(13): 1780-6.
Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., Mukoyama M., Nakao K., Imura H., Sasayama S.. “Ventricular expression of brain natriuretic Peptide in Hypertrophic cardiomyopathy”.Circulation. (1993); 88(2): 372-80.
Bibiografia
Herrmann M., Scharhag J., Miclea M., Urhausen A., Herrmann W., Kindermann W..
“Post-race kinetics of cardiac troponin T and I and N-terminal pro-brain natriuretic peptide in marathon runners”. Clin Chem. 2003 May; 49(5): 831-4.
Holmgren D., Westerlind A., Berggren H., Lundberg P.A., Wåhlander H..
“Increased natriuretic peptide type B level after the second palliative step in children with univentricular hearts with right ventricular morphology but not left ventricular morphology. Pediatric Cardiol (2008); 29: 786-92.
Holmgren D., Westerlind A., Lundberg P. A., Wåhlander H.. “Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload”. Clin Physiol Funct Imaging (2005); 25: 263-9.
Hsu J.H., Keller R.L., Chikovani O., Cheng H., Hollander S.A., Karl T.R., Azakie A., Adatia I., Oishi P., Fineman J.R.. “B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery”. J Thorac Cardiovasc Surg. (2007); 134(4): 939-45.
Hsu J. H., Oishi P. E., Keller R. L., Chikovani O., Karl T. R., Azakie A., Adatia I., Fineman J.R.. “Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection”. J Thorac Cardiovasc Surg. (2008); 135(4): 746-53.
Bibiografia
Hunt P.J., Espiner E.A., Nicholls M. G., Richards A. M., Yandle T. G. “The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32”. Peptides (1997), 18:1475-81.
Ishii H., Harada K., Toyono M., Tamura M., Takada G. “Usefulness of exercise- induced changes in plasma levels of brain natriuretic peptide in predicting right ventricular contractile reserve after repair of tetralogy of Fallot”. Am J Cardiol. (2005);
95(11): 1338-43.
Jacobs J.P., Jacobs M.L., Lacour-Gayet F.G., Jenkins K.J., Gauvreau K., Bacha E., Maruszewski B., Clarke D.R., Tchervenkov C.I., Gaynor J.W., Spray T.L., Stellin G., O'Bien S.M., Elliott M.J., Mavroudis C. “Stratification of complexity improves the utility and accuracy of outcomes analysis in a Multi-Institutional Congenital Heart Surgery Database: Application of the Risk Adjustment in Congenital Heart Surgery (RACHS- 1) and Aristotle Systems in the Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database”. Pediatr Cardiol (2009); 30: 1117-30.
Jamieson J.D., Palade G. E.. “Specific granules in atrial muscle cell”. J. Cell Biol (1964), 23: 151-62.Kanbe T., Maeno Y., Fujino H., Kanda H., Hirose A., Okada J.
Morikawa T., Iwata S., Iwata O., Matsuishi T.. “Brain-type natriuretic peptide at birth reflects foetal maturation and antenatal stress”. Acta Paediatr. 2009; 98(9): 1421-5.
Kelly P., Gaston S., Mackay R, et al.. “Anovel assay for the measurement of plasma B-
Bibiografia
type natriuretic peptide by an AxSYM microparticle based immunoassay with use of stable liquid calibrators”. Clin Chem (2002); 48: A94.
Khositseth A., Manop J., Khowsathit P., Siripornpitak S., Pornkul R., Lolekha P., Attanawanich S.. “. N-terminal pro-brain natriuretic peptide as a marker in follow-up patients with tetralogy of Fallot after total correction”. Pediatr Cardiol. (2007); 28(5):
333-8.
Kirsh B.. “Electronmicroscopy of the atrium of the heart” Exp Med Surg (1956), 14: 99- 112.
Knirsch W, Dodge-Khatami A, Kadner A, Kretschmar O, Steiner J, Böttler P, Kececioglu D, Harpes P, Valsangiacomo Buechel ER. “Assessment of myocardial function in pediatric patients with operated tetralogy of Fallot: preliminary results with 2D strain echocardiography”. Pediatr Cardiol. (2008); 29(4):718-25.
Ko H.K., Lee J.H., Choi B.M., Lee J.H., Yoo K.H., Son C.S., Lee J.W.. “Utility of the rapid B type natriuretic peptide assay for detection of cardiovascular problems in newborn infants with respiratory difficulties”. Neonatology (2008); 94: 16–21.
Koch A., Kitzsteiner T., Zink S., Cesnjevar R., Singer H.. “Impact of cardiac surgery on plasma levels of B-type natriuretic peptide in children with congenital heart disease”.
Int J Cardiol. (2007); 114(3): 339-44.
Bibiografia
Koch A., Singer H.. “Normal values of B type natriuretic peptide in infants, children, and adolescents”. Heart. (2003); 89(8): 875-8.
Koch A. M., Zink S., Glöckler M., Seeliger T., Dittrich S.. “ Plasma levels of B-type natriuretic peptide in patients with tetralogy of Fallot after surgical repair”. Int J Cardiol. (2010); 143(2):130-4.
Koch A., Zink S., Singer H.. “B-type natriuretic peptide in paediatric patients with congenital heart disease”. Eur Heart J (2006); 27: 861–6.
Koch A.M., Zink S., Singer H., Dittrich S.. “B-type natriuretic peptide levels in patients with functionally univentricular hearts after total cavopulmonary connection”. Eur J Heart Fail. (2008); 10(1): 60-2.
Koulouri S., Acherman R.J., Wong P.C., Chan L.S., Lewis A.B.. “Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress” Pediatr Cardiol. (2004); 25(4): 341-6.
Kunii Y., Kamada M., Ohtsuki S., Araki T., Kataoka K., Kageyama M., Nakagawa N., Seino Y..“Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease”. Acta Med Okayama. (2003); 57(4):
191-7.
Bibiografia
La Pointe M.C.. “Molecular regulation of the brain natriuretic gene”. Peptides. (2005), 26: 944-56.
Lan Y.T., Chang R.K., Alejos J.C., Burch C., Wetzel G.T.. “B-type natriuretic peptide in children after cardiac transplantation”. J Heart Lung Transplant. (2004); 23(5): 558- 63.
Latini R., Masson S., Anand I., Salio M., Hester A., Judd D., Barlera S., Maggioni A.P., Tognoni G., Cohn J.N.; Val-HeFT Investigators. “The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT”.
Eur Heart J. (2004); 25(4): 292-9.
Law Y.M., Ettedgui J., Beerman L., Maisel A., Tofovic S.. “Comparison of plasma B- type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure”. Am J Cardiol. (2006); 98(4): 520-4.
Law Y.M., Hoyer A.W., Reller M.D., Silberbach M.. “Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the better not pout children! Study” J Am Coll Cardiol (2009); 54:1467–75.
Lechner E., Gitter R., Mair R., Pinter M., Schreier-Lechner E., Vondrys D., Tulzer G..
“Aminoterminal brain natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive heart failure”. Pediatr Cardiol. (2008); 29(5): 901-
Bibiografia
5.
Lechner E., Schreier-Lechner E.M., Hofer A., Gitter R., Mair R., Biebl A., Tulzer G.
“Aminoterminal brain-type natriuretic peptide levels correlate with heart failure in patients with bidirectional Glenn anastomosis and with morbidity after the Fontan operation”. J Thorac Cardiovasc Surg. (2009); 138(3): 560-4.
Logeart D., Saudubray C., Beyne P., Thabut G., Ennezat P.V., Chavelas C., Zanker C., Bouvier E., Solal A.C.. “Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea”. J Am Coll Cardiol. (2002); 40(10): 1794-800.
Lopez L., Colan S.D., Frommelt P.C., Ensing G.J., Kendall K., Younoszai A.K., Lai W.W., Geva T.. “Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council”. J Am Soc Echocardiogr (2010); 23:465-95.
Ma K.K., Banas K., de Bold A.J.. “Determinants of inducible brain natriuretic peptide promoter activity”. Regul Pept. (2005), 128(3):169-76.
Ma K.K., Ogawa T., de Bold A.J.. “Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and
Bibiografia
by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase”
J Mol Cell Cardiol. (2004) 36(4): 505-13.
Maffei S., Del Ry S., Prontera C., Clerico A.. “Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women”. Clin Sci (Lond). (2001); 101(5): 447-53.
Mair J., Hammerer-Lercher A., Puschendorf B.. “ The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure”. Clin Chem Lab Med. (2001) 39(7): 571-88.
Maisel A.S., Koon J., Krishnaswamy P., Kazenegra R., Clopton P., Gardetto N., Morrisey R., Garcia A., Chiu A., De Maria A.. “Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction”. Am Heart J. (2001); 141(3): 367-74.
Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., McCullough P.A.;
Breathing Not Properly Multinational Study Investigators. “Rapid measurement of B type natriuretic peptide in the emergency diagnosis of heart failure”. N Engl J Med.
(2002); 347(3): 161-7.
Bibiografia
Mannarino S., Ciardelli L., Garofoli F., Perotti G., Mongini E., Damiano S., Tinelli C., Cerbo R.M., Rondini G., Stronati M.. “Correlation between cord blood, perinatal BNP values and echocardiographic parameters in healthy Italian newborns”. Early Hum Dev.
(2009) ; 85(1): 13-7.
Mannarino S., Garofoli F., Cerbo R.M., Perotti G., Mongini E., Codazzi C., Ciardelli L., Tinelli C., De Silvestri A., Stronati M.. “Cord blood, perinatal BNP values in term and preterm newborns”. Arch Dis Child Fetal Neonatal Ed. (2010); 95(1): F74.
Mannarino S., Garofoli F., Mongini E., Cerbo R.M., Codazzi A.C., Tzialla C., Mazzucchelli I., Perotti G., Tinelli C., De Silvestri A., Manzoni P., Stronati M.. “BNP concentrations and cardiovascular adaptation in preterm and fullterm newborn infants”.
Early Hum Dev. (2010); 86(5): 295-8.
Mc Grath M.F. de Bold A.J.. “Determinants of natriuretic peptide gene expression”
Peptides (2005), 26: 933-43.
Mir T.S., Flato M., Falkenberg J., Haddad M., Budden R., Weil J., Albers S., Laer S..“Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender” Pediatr Cardiol. (2006); 27(1):
73-7.
Mir T.S., Haun C., Lilje C., Läer S., Weil J.. “Utility of N-terminal brain natriuretic
Bibiografia
peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery”. Pediatr Cardiol. 2006; 27(2):
209-16.
Mir T.S., Marohn S., La¨er S., Eiselt M., Grollmus O., Weil J.. “Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure”. Pediatrics (2002); 110:
e 76.
Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., Wu A.H., Christenson R.H.; National Academy of Clinical Biochemistry. “National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes”.
Circulation. (2007); 115(13): 356-75.
Mueller C., Laule-Kilian K., Scholer A., Frana B., Rodriguez D., Schindler C., Marsch S., Perruchoud A. P. “Use of B-type natriuretic peptide for the management of women with dyspnea”. Am J Cardiol. (2004); 94(12): 1510-4.
Nakamura M., Endo H., Nasu M., Arakawa N., Segawa T., Hiramori K.. “Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population”. Heart. (2002); 87(2):131-5.
Bibiografia
Neffke J.G., Tulevski I.I., van der Wall E.E., Wilde A.A., van Veldhuisen D.J., Dodge- Khatami A., Mulder B.J..“ECG determinants in adult patients with chronic right ventricular pressure overload caused by congenital heart disease: relation with plasma neurohormones and MRI parameters”. Heart. (2002); 88(3): 266-70.
Niedner Lindblade C.L., Chun D.S., Darragh R.K., Caldwell R.L., Murphy D.J., Schamberger M.S.. “Value of plasma B-type natriuretic peptide as a marker for rejection in pediatric heart transplant recipients”. Am J Cardiol. (2005); 95(7): 909-11.
Niedner M.F., Foley J.L., Riffenburgh R.H., Bichell D.P., Peterson B.M., Rodarte A..
“B-type natriuretic peptide: perioperative patterns in congenital heart disease”. Congenit Heart Dis. (2010); 5(3): 243-55.
Nir A., Bar-Oz B., Perles Z., Brooks R., Korach A., Rein A.J.. “N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases”. Acta Paediatr. (2004); 93(5): 603- 7.
Nir A., Lindinger A., Rauh M., Bar-Oz B., Laer S., Schwachtgen L., Koch A., Falkenberg J., Mir T.S.. “NT-pro-B-type natriuretic peptide in infants and children:
reference values based on combined data from four studies”. Pediatr Cardiol. (2009);
30(1): 3-8.
Bibiografia
Norozi K., Buchhorn R., Kaiser C., Hess G., Grunewald R.W., Binder L., Wessel A..
“Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair”. Chest. (2005);
128(4): 2563-70.
Nousiainen T., Jantunen E., Vanninen E., Remes J., Vuolteenaho O., Hartikainen J..
“Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non- Hodgkin's lymphoma”. Eur J Haematol. (1999); 62(2): 135-41.
Nybo M., Nielsen L.B., Nielsen S.J., Lindegaard M., Damm P., Rehfeld J.F., Goetze J.P.. “Discordant expression of pro-B-type and pro-C-type natriuretic peptide in newborn infants of mothers with type 1 diabetes”. Regul Pept. (2007) 7; 141(1-3): 135- 9.
Okumura H., Iuchi K., Yoshida T., Nakamura S., Takeshima M., Takamatsu H., Ikeno A., Usuda K., Ishikawa T., Ohtake S., Matsuda T.. “Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity”. Acta Haematol. (2000); 104(4): 158- 63.
Oosterhof T., Tulevski I.I., Vliegen H.W., Spijkerboer A.M., Mulder B.J.. “Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels”. Am J Cardiol. (2006);
Bibiografia
97(7): 1051-5.
Packer M.. “The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure” J Am Coll Cardiol. (1992); 20(1): 248-54.
Panteghini M., Clerico A.. “Understanding the clinical biochemistry of N-terminal pro- B-type natriuretic peptide: the prerequisite for its optimal clinical use”. Clin Lab.
(2004b); 50(5-6): 325-31.
Pantegnini M., Belloni A., Botta M., Dominaci R., Luraschi P., Magenta M. et al
“Strategie per l’impiego dei biomarcatori cardiaci: raccomandazioni e protocolli oprativi”. Biochim Clin 2005, 29: 419-28.
Pantegnini M. “ Current concepts in standardization of cardiac markers immunoassay”.
Clin Chem Lab Med (2004a); 42: 3-8.
Passino C., Severino S., Poletti R., Piepoli M.F., Mammini C., Clerico A., Gabutti A., Nassi G., Emdin M.. “Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure “. J Am Coll Cardiol. (2006);
47(9): 1835-9.
Passino C., Ry S.D., Severino S., Gabutti A., Prontera C., Clerico A., Giannessi D., Emdin M.. “C-type natriuretic peptide expression in patients with chronic heart failure:
Bibiografia
effects of aerobic training”. Eur J Cardiovasc Prev Rehabil (2008); 15: 168-172.
Paul M.A., Backer C.L., Binns H.J., Mavroudis C., Webb C.L., Yogev R., Franklin W.H.. “B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study”. Pediatr Cardiol. (2009); 30(8): 1094-7.
Prontera C., Storti S., Emdin M., Passino C., Zyw L., Zucchelli G.C., Clerico A..
“Comaprison of a fully automated immunoassay with a point-of care testing method for B-type natriuretic peptide”. Clin Chem . (2005); 51: 1274-6.
Prontera C., Zaninotto M., Giovannini S., Zucchelli G.C., Pilo A., Sciacovelli L., Plebani M., Clerico A.. “Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study”. Clin Chem Lab Med (2009); 47: 762-8.
Rauh M., Koch A.. “Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children”. Clin Chem. (2003); 49(9): 1563-4.
Richards A. M., Lainchbury J. G., Nicholls M. G., Cameron A. V., Yandle T. G..
“Dendroaspis natriuretic peptide: endogenous or dubious?” Lancet. (2002); 359(9300):
5-6.
Robbers- Visser D., Kapusta L., van Osch-Gevers L., Strengers J .L., Boersma E., de
Bibiografia
Rijke Y.B., Boomsma F., Bogers A.J., Helbing W.A.. “Clinical outcome 5 to 18 years after the Fontan operation performed on children younger than 5 years”. J Thorac Cardiovasc Surg. (2009); 138(1): 89-95.
Robin X., Turck N., Hainard A., Tiberti N., Lisacek F., Sanchez J.C., Müller M.
“pROC: an opensource package for R and S+ to analyze and compare ROC curves”.
BMC Bioinformatics (2011); 12: 77.
Rudolph A.M.. “Congenital cardiovascular malformation and the fetal circulation”.
Arch Dis Child Fetal Neonatal Ed (2010); 95: F132-6.
Sagnella G.A.. “Measurement and importance of plasma brain natriuretic peptide and related peptides.”. Ann Clin Biochem. (2001); 38(Pt 2):83-93.
Sagnella G.A.. “Measurement and significance of circulating natriuretic peptides in cardiovascular disease”. Clin Sci (Lond). (1998) 95(5): 519-29.
Şahin M., Portakal O., Karagöz T., Hasçelik G., Özkutlu S.. “Diagnostic performance of BNP and NT-ProBNP measurements in children with heart failure based on congenital heart defects and cardiomyopathies”. Clin Biochem. (2010);43(16-17): 1278-81.
Sakata Y., Yamamoto K., Masuyama T., Mano T., Nishikawa N., Kuzuya T., Miwa T., Hori M. J.. “Ventricular production of natriuretic peptides and ventricular structural
Bibiografia
remodeling in hypertensive heart failure”. Hypertens. (2001);19(10): 1905-12.
Schulz-Knappe P., Forssmann K., Hock D., Pipkorn R., Forssmann W. G.. “Isolation and structural analysis of urodilaion, a new peptide of the cardiodilation (ANP) family, extractedfrom human urine”. Klin Wochenschr (1988); 66: 752-9.
Sanjeev S., Pettersen M., Lua J., et al. “Role of plasma Btype natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates”. J Perinatol (2005); 25: 709–13.
Shih C.Y., Sapru A., Oishi P., Azakie A., Karl T.R., Harmon C., Asija R., Adatia I., Fineman J.R.. “Alterations in plasma B-type natriuretic peptide levels after repair of congenital heart defects: a potential perioperative marker”. J Thorac Cardiovasc Surg.
(2006); 131(3): 632-8.
Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W.G..
“Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin- (ANP)-family, extracted from human urine” Klin Wochenschr. (1988); 66(17): 752-9.
Sinha A.M., Breithardt O.A., Schmid M., Stellbrink C.. “Brain natriuretic peptide release in cardiac surgery patients”. Thorac Cardiovasc Surg (2005); 53:138-43.
Smith A. C., Wu A .H.. “ Analitical performance evaluationof the Bayer Advia Centaur
Bibiografia
BNP immunoassay”. Clin Chem (2003); 49 (suppl): A71.
Shimizu H., Aono K., Masuta K., Asada H., Misaki A., Teraoka H. “Degradetion of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chem Acta (2001); 305: 181-6.
Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., Tamaki M., et al. “Molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta (2003); 334:
233-9.
Socrates T., Arenja N., Mueller C.. “B-type natriuretic peptide in children: step by step”. J Am Coll Cardiol (2009); 54:1476–7.
Soldin S.J., Morales A., Albalos F., Lenherr S., Rifai N.. “Pediatric reference ranges on the Abbott IMx for FSH, LH, prolactin, TSH, T4, T3, free T4, free T3, T-uptake, IgE, and ferritin”. Clin Biochem. (1995); 28(6): 603-6.
Soldin S.J., Soldin O.P., Boyajian A.J., Taskier M.S.. “Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals”. Clin Chim Acta. (2006); 366(1-2): 304-8.
Spevack D. M., Schwaartzbard A. “B-type natriuretic peptide measurement in heart failure”. Clin Cardiol (2004); 27: 489-494.
Bibiografia
Sudoh T., Maekawa K., Kojima M., Minamino N., Kangawa K., Matsuo H.. “Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide”. Biochem Biophys Res Commun. (1989) 159(3): 1427-34.
Sudoh T., Minamino N., Kangawa K., Matsuo H. “A new natriuretic peptide in porcine brain”. Nature (1988); 332: 78-81.
Sudoh T., Minamino N., Kangawa K., Matsuo H.. “C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain”. Biochem Biophys Res Commun. (1990); 168(2) 863-70.
Suzuki S., Yamamoto K., Ogata M., Kondo H., Sugiura M., Shigeyama J., Itoh M..
“Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction”. Am J Cardiol. (2004) 94(4):448-53.
Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., Kurabayashi M., Yamaoki K., Mitani K., Hirai H., Nagai R., Yazaki Y.. “Elevated B-type natriuretic peptide levels after anthracycline administration”. Am Heart J. (1998); 136(2): 362-3.
Suzuki T., Yamazaki T., Yazaki Y.. “The role of the natriuretic peptides in the cardiovascular system.” Cardiovasc Res. (2001); 51(3):489-94.
Bibiografia
Swedberg K., Cleland J., Dargie H., Drexle r H., Follath F., Komajda M., Tavazzi L., Smiseth O.A., Gavazzi A., Haverich A., Hoes A., Jaarsma T., Korewicki J., Lévy S., Linde C., Lopez-Sendon J.L., Nieminen M.S., Piérard L., Remme W.J.; “Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology”. Eur Heart J. (2005) 26(11): 1115-40.
Szymański P., Klisiewicz A., Lubiszewska B., Lipczyńska M., Michałek P., Janas J., Hoffman P.. “Application of classic heart failure definitions of asymptomatic and symptomatic ventricular dysfunction and heart failure symptoms with preserved ejection fraction to patients with systemic right ventricles”. Am J Cardiol. (2009) 1;
104(3): 414-8.
Talha S., Charloux A., Enache I., Piquard F., Geny B. “Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation”. Cardiovasc Res (2011); 89:273- 81.
Takeda Y., Fukutomi T., Suzuki S., Yamamoto K., Ogata M., Kondo H., Sugiura M., Shigeyama J., Itoh M.. “Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction”. Am J Cardiol. (2004); 94(4): 448-53.
Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., StorrowA. B., Christenson R. H.; NACB Committee. “National Academy of Clinical
Bibiografia
Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure”. Circulation (2007);116: 99-109.
Tang W.H., Girod J.P., Lee M.J., Starling R.C., Young J.B., Van Lente F., Francis G.S..
“Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure”. Circulation. (2003); 108(24): 2964-6.
Trojnarska O., Gwizdała A., Katarzyński S., Katarzyńska A., Szyszka A., Lanocha M., Grajek S., Kramer L.. “Evaluation of exercise capacity with cardiopulmonary exercise test and B-type natriuretic peptide in adults with congenital heart disease” Cardiol J.
(2009); 16(2): 133-41.
Tulevski I.I., Hirsch A., Sanson B.J., Romkes H., van der Wall E.E., van Veldhuisen D.J., Büller H.R., Mulder B.J. “Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism”. Thromb Haemost. (2001);
86(5): 1193-6.
Van Den Berg J., Strengers J.L., Wielopolski P.A., Hop W. C., Meijboom F.J., de Rijke Y.B., Boomsma F., Bogers A.J., Pattynama P.M., Helbing W.A.. “Assessment of biventricular functional reserve and NT-proBNP levels in patients with RV volume overload after repair of tetralogy of Fallot at young age”. Int J Cardiol. (2009); 133(3):
364-70.
Bibiografia
Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., Levy D..
“Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study”. JAMA. (2002);288(10): 1252-9.
Walsh R., Boyer C., LaCorte J., Parnell V., Sison C., Chowdhury D., Ojamaa K.. “N- terminal B-type natriuretic peptide levels in pediatric patients with congestive heart failure undergoing cardiac surgery”. J Thorac Cardiovasc Surg. (2008); 135(1): 98-105.
Wernovsky G., Wypij D., Jonas R.A., Mayer J.E. Jr, Hanley F.L., Hickey P.R., Walsh A. Z., Chang A.C., Castañeda A.R., Newburger J.W., et al. “.Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest”. Circulation.
(1995); 92(8): 2226-35.
Wheeldon M.N., MacDonald T.M., Flucker C. J., McKendrlck A.D., McDevitt D.C., Struthers A. D. “Echocardiography in chronic heart failure in the community”. Quart J Med (1993), 86:17-23.
Wiviott S.D., de Lemos J.A., Morrow D,A.. “Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes”. Clin Chim Acta. (2004) Aug; 346(2): 119-28.
Yamamoto K., Burnett J. C. Jr, Bermudez E.A., Jougasaki M., Bailey K .R., Redfield
Bibiografia
M.M.. “Clinical criteria and biochemical markers for the detection of systolic dysfunction”. J Card Fail. (2000); 6(3): 194-200.
Yoshibayashi M., Kamiya T., Saito Y., Nakao K., Nishioka K., Temma S., Itoh H., Shirakami G., Matsuo H.. “Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth”. Eur J Endocrinol. (1995); 133(2): 207-9.
Yuan S.M., Jing H.. “Palliative procedures for congenital heart defects”. Arch Cardiovasc Dis. (2009); 102 (6-7) 549-57.
